Literature DB >> 1483494

Serum concentration-effect relationship of (+/-)-nicardipine and nifedipine in elderly hypertensive patients.

H C Porchet1, F Loew, L Gauthey, P Dayer.   

Abstract

The concentration-effect relationships of (+/-)-nicardipine and nifedipine have been investigated in hypertensive geriatric patients. Following a parallel group, randomised, double blind trial design, they received either slow release nifedipine 20 mg b.d. (n = 9) or slow release (+/-)-nicardipine 50 mg b.d. (n = 10) for 7 days. On Days 1 and 7 serum (+/-)-nicardipine and nifedipine, blood pressure and heart rate were measured 6 and 12 h after drug administration. (+/-)-Nicardipine showed significant cumulation (ca 2 x) without a corresponding decrease in blood pressure or increase in heart rate. Concentration-effect plots indicated that (+/-)-nicardipine was more potent than nifedipine but that it showed apparently comparable efficacy in reducing the blood pressure. Compared to young healthy volunteers, both drugs had a more pronounced effect in elderly patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1483494     DOI: 10.1007/bf02285101

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Serum concentrations and effects of (+/-)-nicardipine compared with nifedipine in a population of healthy subjects.

Authors:  H C Porchet; P Dayer
Journal:  Clin Pharmacol Ther       Date:  1990-08       Impact factor: 6.875

Review 2.  Animal pharmacology of nicardipine and its clinical relevance.

Authors:  R L Whiting
Journal:  Am J Cardiol       Date:  1987-06-30       Impact factor: 2.778

3.  Development of tolerance to nifedipine in patients with stable angina pectoris.

Authors:  S Y Martsevich; V I Metelitsa; D O Rumiantsev; V K Piotrovskii; I D Slastnikova; L V Egorov; V A Vygodin
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

4.  Initial blood pressure as a predictor of the response to antihypertensive therapy.

Authors:  D J Sumner; P A Meredith; C A Howie; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

Review 5.  Calcium channel blockers in systemic hypertension.

Authors:  W H Frishman; S Charlap; E L Michelson
Journal:  Am J Cardiol       Date:  1986-07-01       Impact factor: 2.778

6.  Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans.

Authors:  C H Kleinbloesem; P van Brummelen; M Danhof; H Faber; J Urquhart; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

7.  Uptake of calcium antagonistic drugs into muscles as related to their lipid solubilities.

Authors:  D C Pang; N Sperelakis
Journal:  Biochem Pharmacol       Date:  1984-03-01       Impact factor: 5.858

8.  Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.

Authors:  T S Foster; S R Hamann; V R Richards; P J Bryant; D A Graves; R G McAllister
Journal:  J Clin Pharmacol       Date:  1983-04       Impact factor: 3.126

Review 9.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 10.  Guidelines for treating hypertension in the elderly.

Authors:  J P Emeriau
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

  10 in total
  3 in total

Review 1.  Calcium signalling through L-type calcium channels: role in pathophysiology of spinal nociceptive transmission.

Authors:  Olivier Roca-Lapirot; Houda Radwani; Franck Aby; Frédéric Nagy; Marc Landry; Pascal Fossat
Journal:  Br J Pharmacol       Date:  2017-03-24       Impact factor: 8.739

2.  Knockdown of L calcium channel subtypes: differential effects in neuropathic pain.

Authors:  Pascal Fossat; Eric Dobremez; Rabia Bouali-Benazzouz; Alexandre Favereaux; Sandrine S Bertrand; Kalle Kilk; Claire Léger; Jean-René Cazalets; Ulo Langel; Marc Landry; Frédéric Nagy
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

Review 3.  Calcium antagonists in the elderly. A risk-benefit analysis.

Authors:  J B Schwartz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.